Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NATCO Pharma Limited ( (IN:NATCOPHARM) ) has provided an update.
Natco Pharma Limited announced that its pharmaceutical division in Kothur, Hyderabad, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA), classifying the facility as ‘Voluntary Action Indicated’ (VAI). This classification indicates that the FDA inspection found some issues that need correction but are not significant enough to warrant regulatory action. The VAI status is a positive outcome for Natco Pharma as it allows the company to continue its operations without major disruptions, potentially enhancing its credibility and market position in the pharmaceutical industry.
More about NATCO Pharma Limited
Natco Pharma Limited operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of generic pharmaceuticals. The company is based in Hyderabad, India, and is known for its strong presence in the production of oncology and other critical care products.
Average Trading Volume: 67,571
Technical Sentiment Signal: Sell
Current Market Cap: 152.6B INR
Find detailed analytics on NATCOPHARM stock on TipRanks’ Stock Analysis page.